The Zhitong Finance App learned that Kingsley Biotech (01548) rose nearly 9% in early trading. As of press release, it rose 7.18% to HK$35.82, with a turnover of HK$386 million.

According to the news, Kingsley Biotech recently announced that LEGENDARY BIOTECH disclosed that CARVYKTI's net trade sales for the third quarter of 2026 were approximately US$710 million. Combined with revenue of US$1,254 million in the first half of the year, Carvykti's cumulative sales for the first three quarters were approximately US$1,964 million, an increase of 47.4% over the previous year. Judging from the quarterly trend, the product sold 597 million US dollars in Q1, reached 657 million US dollars in Q2, and further climbed to 710 million US dollars in Q3, and continued to increase from month to month.

Notably, on September 16, Kingsley Biotech announced a partnership with Lilly TuneLab, Eli Lilly's AIDD collaboration platform. According to the agreement, the company will provide wet testing services to TuneLab participating companies to help them quickly generate experimental data, transform AI predictions into biological verification data, and accelerate the evaluation of drug candidates. J.P. Morgan said the move is a strategic entry point into the ecosystem of more than 100 Biotech customers and open up a closed loop of wet and dry testing.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.